Weaponized Safety: How the FDA Is Killing mRNA
The FDA's refusal to review Moderna's flu vaccine isn't about safety. It is about a retroactive change in math that protects incumbents and drives innovation offshore.
2 articles
The FDA's refusal to review Moderna's flu vaccine isn't about safety. It is about a retroactive change in math that protects incumbents and drives innovation offshore.
RFK Jr. slashes mRNA funding while the CDC delays Hepatitis B vaccines. A cynical look at how disease outbreaks could fuel a volatile new era for biotech stocks.